- Trial phase
- Approved (China); Phase 3 first-line data filed for approval
- Time to market
- Already approved in China (the 6-K calls it an "approved asset"); US/EU timeline not yet announced by AstraZeneca
- Why 3/10
- No hard, dated binary catalyst verified for sunvozertinib in the next ~12 months: it is an already-approved asset (China) that AstraZeneca just licensed globally (deal 6-K filed July 14, 2026), and the first-line approval filing has no public decision date, plus, for a ~$240-260B mega-cap this one in-licensed drug is a minor share-price driver, so it scores in the approved/no-pending-decision band rather than the binary-catalyst band.
Watch for (1) the China first-line indication decision and (2) any AstraZeneca regulatory submissions for Zegfrovy in the US/EU, plus whether AZN pays out the up-to-$900M milestones to Dizal, milestone payouts signal successful global filings. Treat this as franchise-building context for AZN's lung-cancer portfolio (Tagrisso et al.), not a standalone share-price event: the $600M upfront is tiny relative to AZN's market cap.
Price Chart
Executive Summary
Sunvozertinib (brand Zegfrovy) is an oral EGFR-inhibitor pill for non-small cell lung cancer with EGFR exon 20 insertion mutations, originally developed by China's Dizal Pharmaceutical. On July 14, 2026 AstraZeneca filed a 6-K announcing an exclusive global license: AZN pays Dizal $600M upfront plus up to $900M in milestones plus tiered royalties, adding an already-approved asset to AZN's lung-cancer franchise, with positive Phase III data already filed for first-line use. For AZN, a mega-cap trading near $156 with a strong-buy analyst consensus (13 strong buy/16 buy/5 hold/1 sell; mean target $213.69), the drug is a sensible bolt-on but not a share-price catalyst on its own, and it faces a competitive US market where no sunvozertinib approval exists yet.
How It Works
A once-a-day pill that blocks a specific mutated protein (EGFR with exon 20 insertions) which drives a form of non-small cell lung cancer. By switching off that growth signal, the drug can shrink or slow the tumor in patients whose cancer has that particular genetic fingerprint.
Trial Status
Per AstraZeneca's July 2026 6-K report: sunvozertinib is an approved oral EGFR inhibitor, and "positive Phase III data" have "already been filed for first-line use." No FDA action on the drug is recorded in SecBot's FDA data, meaning no US approval or PDUFA is on file yet.
The Two-Sided Case
Upcoming Catalysts
- China (NMPA) decision on the first-line EGFR exon-20 insertion indication filing, no public date verified
- Any AstraZeneca regulatory submissions for Zegfrovy in the US/EU (would trigger milestone payments to Dizal)
- Commercial uptake data for the approved China indication
- Competitive dynamics vs. already-approved exon-20 therapies in the US market
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ASTRAZENECA PLC 6-K AZN ·Originating report